CoChat

Tirzepatide: First Approval

Syed, Yahiya Y. · 2022 · Drugs

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion. GIP also plays a role in nutrient and energy metabolism, while GLP-1 also delays gastric emptying, supresses appetite and improves satiety. Eli Lilly is developing tirzepatide for the treatment of type 2 diabetes mellitus (T2DM), obesity, cardiovascular disorders in T2DM, heart failure, non-alcoholic steatohepatitis, obstructive sleep apnoea and for reducing mortality/morbidity in obesity. In May 2022, tirzepatide received its first approval in the USA to improve glycaemic control in adults with T2DM, as an adjunct to diet and exercise. Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis. This article summarizes the milestones in the development of tirzepatide leading to this first approval for T2DM.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-022-01746-8

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 144

Metadata

Authors
Syed, Y. Y.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Syed, Yahiya Y.
Venue
Drugs
Published
2022-07
Volume
82
Issue
11
Pages
1213-1220
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W4285087957
Cited by
144
References
20
Citations by year
2026: 27 · 2025: 45 · 2024: 35 · 2023: 31 · 2022: 6
FWCI
21.68
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, GIP/GLP-1 dual agonist, type 2 diabetes, obesity, heart failure, nonalcoholic steatohepatitis, obstructive sleep apnea, incretins, glycemic control, drug approval, drug development
MeSH terms
Glucagon-Like Peptide-1 Receptor, Tirzepatide, Adult, Diabetes Mellitus, Type 2, Fatty Liver, Gastric Inhibitory Polypeptide, Heart Failure, Humans, Obesity, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide: First Approval. https://app.cochat.ai/papers/10.1007/s40265-022-01746-8
The paper
Syed, Y. Y. (2022). Tirzepatide: First Approval. Drugs. https://doi.org/10.1007/s40265-022-01746-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.